Engineered cells as glioblastoma therapeutics
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as gliob...
Gespeichert in:
| Veröffentlicht in: | Cancer gene therapy 2022-02, Vol.29 (2), p.156-166 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 2 |
| container_start_page | 156 |
| container_title | Cancer gene therapy |
| container_volume | 29 |
| creator | Ramanathan, Aparna Lorimer, Ian A. J. |
| description | In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy. |
| doi_str_mv | 10.1038/s41417-021-00320-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629160308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-9c77eeffd60f594a223fac83cd4ea76d93de899d0b0a132452bab49e46a382b03</originalsourceid><addsrcrecordid>eNp9kUlPwzAQhS0EoqXwBzigSly4GMZL4viChKqySEhc4Gw5ySRNlaXYCRX_npSUshw4-fC-eeM3j5BTBpcMRHTlJZNMUeCMAggOdL1HxkyqkAYBwD4Zg-aaMg1iRI68XwL0ohKHZCSECkQU6jGh8zovakSH6TTBsvRT66d5WTRxaX3bVHbaLtDZFXZtkfhjcpDZ0uPJ9p2Ql9v58-yePj7dPcxuHmkilWypTpRCzLI0hCzQ0nIuMptEIkklWhWmWqQYaZ1CDJYJLgMe21hqlKEVEY9BTMj14Lvq4grTBOvW2dKsXFFZ924aW5jfSl0sTN68mSgKYBN4Qi62Bq557dC3pir8Jp-tsem84QFIEXBQukfP_6DLpnN1H8_wkGsWgoCop_hAJa7x3mG2-wwDs2nDDG2Yvg3z2YZZ90NnP2PsRr7O3wNiAHwv1Tm6793_2H4ALM6WDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629160308</pqid></control><display><type>article</type><title>Engineered cells as glioblastoma therapeutics</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ramanathan, Aparna ; Lorimer, Ian A. J.</creator><creatorcontrib>Ramanathan, Aparna ; Lorimer, Ian A. J.</creatorcontrib><description>In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/s41417-021-00320-w</identifier><identifier>PMID: 33753869</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/67/1922 ; 692/308/153 ; Biomedical and Life Sciences ; Biomedicine ; Brain cancer ; Cell- and Tissue-Based Therapy ; Gene Expression ; Gene Therapy ; Glioblastoma ; Glioblastoma - genetics ; Glioblastoma - therapy ; Humans ; Lymphocytes T ; Mesenchyme ; Neural stem cells ; Review ; Review Article ; Stem cells</subject><ispartof>Cancer gene therapy, 2022-02, Vol.29 (2), p.156-166</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</rights><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-9c77eeffd60f594a223fac83cd4ea76d93de899d0b0a132452bab49e46a382b03</citedby><cites>FETCH-LOGICAL-c474t-9c77eeffd60f594a223fac83cd4ea76d93de899d0b0a132452bab49e46a382b03</cites><orcidid>0000-0002-2128-348X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41417-021-00320-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41417-021-00320-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33753869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramanathan, Aparna</creatorcontrib><creatorcontrib>Lorimer, Ian A. J.</creatorcontrib><title>Engineered cells as glioblastoma therapeutics</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.</description><subject>631/67/1922</subject><subject>692/308/153</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain cancer</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Glioblastoma</subject><subject>Glioblastoma - genetics</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Lymphocytes T</subject><subject>Mesenchyme</subject><subject>Neural stem cells</subject><subject>Review</subject><subject>Review Article</subject><subject>Stem cells</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUlPwzAQhS0EoqXwBzigSly4GMZL4viChKqySEhc4Gw5ySRNlaXYCRX_npSUshw4-fC-eeM3j5BTBpcMRHTlJZNMUeCMAggOdL1HxkyqkAYBwD4Zg-aaMg1iRI68XwL0ohKHZCSECkQU6jGh8zovakSH6TTBsvRT66d5WTRxaX3bVHbaLtDZFXZtkfhjcpDZ0uPJ9p2Ql9v58-yePj7dPcxuHmkilWypTpRCzLI0hCzQ0nIuMptEIkklWhWmWqQYaZ1CDJYJLgMe21hqlKEVEY9BTMj14Lvq4grTBOvW2dKsXFFZ924aW5jfSl0sTN68mSgKYBN4Qi62Bq557dC3pir8Jp-tsem84QFIEXBQukfP_6DLpnN1H8_wkGsWgoCop_hAJa7x3mG2-wwDs2nDDG2Yvg3z2YZZ90NnP2PsRr7O3wNiAHwv1Tm6793_2H4ALM6WDw</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Ramanathan, Aparna</creator><creator>Lorimer, Ian A. J.</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2128-348X</orcidid></search><sort><creationdate>20220201</creationdate><title>Engineered cells as glioblastoma therapeutics</title><author>Ramanathan, Aparna ; Lorimer, Ian A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-9c77eeffd60f594a223fac83cd4ea76d93de899d0b0a132452bab49e46a382b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>631/67/1922</topic><topic>692/308/153</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain cancer</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Glioblastoma</topic><topic>Glioblastoma - genetics</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Lymphocytes T</topic><topic>Mesenchyme</topic><topic>Neural stem cells</topic><topic>Review</topic><topic>Review Article</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramanathan, Aparna</creatorcontrib><creatorcontrib>Lorimer, Ian A. J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramanathan, Aparna</au><au>Lorimer, Ian A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineered cells as glioblastoma therapeutics</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>29</volume><issue>2</issue><spage>156</spage><epage>166</epage><pages>156-166</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>33753869</pmid><doi>10.1038/s41417-021-00320-w</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2128-348X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-1903 |
| ispartof | Cancer gene therapy, 2022-02, Vol.29 (2), p.156-166 |
| issn | 0929-1903 1476-5500 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850190 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 631/67/1922 692/308/153 Biomedical and Life Sciences Biomedicine Brain cancer Cell- and Tissue-Based Therapy Gene Expression Gene Therapy Glioblastoma Glioblastoma - genetics Glioblastoma - therapy Humans Lymphocytes T Mesenchyme Neural stem cells Review Review Article Stem cells |
| title | Engineered cells as glioblastoma therapeutics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A16%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineered%20cells%20as%20glioblastoma%20therapeutics&rft.jtitle=Cancer%20gene%20therapy&rft.au=Ramanathan,%20Aparna&rft.date=2022-02-01&rft.volume=29&rft.issue=2&rft.spage=156&rft.epage=166&rft.pages=156-166&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/s41417-021-00320-w&rft_dat=%3Cproquest_pubme%3E2629160308%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2629160308&rft_id=info:pmid/33753869&rfr_iscdi=true |